Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mosapride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 4/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | HTR1A | P08908 | 1/20 | 0.85 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.85 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.85 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.85 |
| ▸ | HTR2C | P28335 | 1/20 | 0.85 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.85 |
| ▸ | HTR2B | P41595 | 1/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.85 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.85 |
| ▸ | DRD4 | P21917 | 12/20 | 0.47 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mosapride SCHEMBL8462520 | 1.00 | DRD3 (0.85) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL1098769 | 0.99 | DRD3 (0.84) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL6227414 | 0.99 | DRD3 (0.84) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL14320968 | 0.99 | DRD3 (0.84) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL30450705 | 0.99 | DRD3 (0.84) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL6229365 | 0.92 | DRD3 (0.91) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL29400580 | 0.92 | DRD3 (1.00) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL6228981 | 0.92 | DRD3 (1.00) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL16417 | 0.92 | DRD3 (1.00) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL6225436 | 0.91 | DRD3 (0.98) | DRD3MEN1LMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1062 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119827654-A | Method for detecting content of genotoxic impurities in mosapride citrate | 珠海润都制药股份有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119700689-A | Pharmaceutical composition containing esomeprazole magnesium and mosapride citrate and preparation method thereof | 浙江京新药业股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119241461-A | Mosapride citrate impurity compound and preparation method thereof | 吉林修正药业新药开发有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119241463-A | Mosapride citrate impurity compound and preparation method thereof | 吉林修正药业新药开发有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119246725-A | Method for detecting fluorine impurities in mosapride citrate intermediate | 吉林修正药业新药开发有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119246710-A | Method for detecting fluorine impurities in mosapride citrate intermediate | 吉林修正药业新药开发有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119241460-A | Mosapride citrate impurity compound and preparation method thereof | 吉林修正药业新药开发有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119241462-A | Mosapride composition, preparation method and application thereof | 吉林修正药业新药开发有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119241464-A | Mosapride citrate impurity compound and preparation method thereof | 吉林修正药业新药开发有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119224147-A | Detection method for mosapride citrate intermediate impurities | 吉林修正药业新药开发有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-1853636-A | Citric acid Mosabily oral liquid | LUNAN PHARMACEUTICAL GROUP CO (CN) | 2006-11-01 | — | — | CN | claimed |
| EP-1695699-A1 | DRUG-CONTAINING GRAINS AND SOLID PREPARATION CONTAINING THE GRAINS | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-08-30 | — | — | EP | claimed |
| CN-1226295-C | Synthesis of Important intermediate for mosapride citrate | LUNAN PHARM CO LTD (CN) | 2005-11-09 | — | — | CN | claimed |
| CN-1615877-A | Mosapride citrate oral solution | LUNAN PHARM CO LTD (CN) | 2005-05-18 | — | — | CN | claimed |
| EP-1515958-A2 | PROCESS FOR THE SYNTHESIS OF MOSAPRIDE | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2005-03-23 | — | — | EP | claimed |
| CN-1526700-A | Synthesis of Important intermediate for mosapride citrate | 鲁南制药股份有限公司 | 2004-09-08 | — | — | CN | claimed |
| CN-1150902-C | Prescription of preparing moxapride citrate | 成都康弘科技实业（集团）有限公司 | 2004-05-26 | — | — | CN | claimed |
| WO-2003106440-A2 | PROCESS FOR THE SYNTHESIS OF A BENZAMIDE DERIVATIVE | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-12-24 | — | — | WO | claimed |
| CN-1359680-A | Pharmaceutical formulation of mosapride citrate | KANGHONG PHARMACEUTICAL CO LTD (CN) | 2002-07-24 | — | — | CN | claimed |
| US-6413541-B1 | DISSOLVING A SACCHARIDE, MIXING THE SOLUTION WITH EXCIPIENT; GRADULATION, DRYING, TABLETTING; AGING | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2002-07-02 | — | — | US | claimed |